Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

Mostrar otras versiones (1)

Vaccines and drugs have helped reduce disease severity and blunt the spread of SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susce...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghadasi, Seyed Arad, Heilmann, Emmanuel, Khalil, Ahmed Magdy, Nnabuife, Christina, Kearns, Fiona L., Ye, Chengjin, Moraes, Sofia N., Costacurta, Francesco, Esler, Morgan A., Aihara, Hideki, von Laer, Dorothee, Martinez-Sobrido, Luis, Palzkill, Timothy, Amaro, Rommie E., Harris, Reuben S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387136/
https://www.ncbi.nlm.nih.gov/pubmed/35982678
http://dx.doi.org/10.1101/2022.08.07.503099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387136/
https://www.ncbi.nlm.nih.gov/pubmed/35982678
http://dx.doi.org/10.1101/2022.08.07.503099

Ejemplares similares